In a mouse model of prostate cancer, oncolytic treatment was dependent on DCs for chemoattractant synthesis, activation of NK cells, and presentation of tumor-associated antigen (TAA) to tumor-specific CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.